DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (2032)

Glaucoma | Access & Reimbursement | Detailed, Expanded Analysis (US)

Glaucoma | Access & Reimbursement | Detailed, Expanded Analysis (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Coming Soon – August 2019

Glaucoma is a chronic and progressive disease of the optic nerve and is one of the leading causes of vision loss. Although the U.S. glaucoma therapy market is crowded and highly genericized, branded therapies have an important role. Recent-to-market therapies—Bausch + Lomb’s Vyzulta and Aerie Pharmaceuticals’ Rhopressa—and late-phase agents (e.g., Aerie’s Rocklatan, Allergan’s bimatoprost sustained release) offer some clinical benefits over current therapies. However, market access decisions for these therapies will play a key role in influencing ophthalmologists’ prescribing habits in glaucoma. Therefore, it is essential to assess how U.S. physicians and payers react to new brands entering a largely generic glaucoma market.


  • Does coverage of therapies for glaucoma differ on MCOs’ largest Medicare Advantage and commercial insurance plans? How do various cost-control measures impact prescribing of current therapies for glaucoma?
  • How are payers covering Vyzulta and Rhopressa on their largest risk-based commercial insurance plans? How do pharmacoeconomic/health economic outcomes data impact formulary decision making for therapies for glaucoma?
  • What points of differentiation are/will be most compelling to ophthalmologists and most convincing to payers for new therapies for glaucoma?
  • Do physicians expect to prescribe key late-phase emerging therapies, including Rocklatan and bimatoprost sustained release, to their glaucoma patients? How do payers intend to reimburse these emerging agents and how will those decisions affect prescribing?


Geography: United States

Primary Research: Survey of ~100 U.S. ophthalmologists, survey of ~30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs)

Key Drugs Covered: Travatan Z, Combigan, Lumigan, Simbrinza, Vyzulta, Rhopressa, Rocklatan, bimatoprost sustained release, latanoprost

Content highlights:

Reimbursement and contracting

Access and prescribing

Special topics

Opportunities and challenges for emerging therapies


U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Coming Soon
      • Coming Soon

Already a Client? Log in to access this report.

  • Pub Date: February 2019
  • Author(s): Himanshu Jain, M.S. Pharm
  • Himanshu is a Lead Analyst in the CNS/Ophthalmology team at Decision Resources Group, and has authored content for indications including age-related macular degeneration, diabetic retinopathy/diabetic macular edema, and unipolar depression. He comes with eight years of experience working on commercial assessment projects, including opportunity assessments, market intelligence, disease narratives, epi-based forecasts, patent research, and social media analysis, across multiple therapy areas. He holds a degree in Pharmacology from the National Institute of Pharmaceutical Education and Research (NIPER) in India and an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.

Purchase Report

Recent reports:
You may also be interested in: